JP2001513511A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001513511A5 JP2001513511A5 JP2000506991A JP2000506991A JP2001513511A5 JP 2001513511 A5 JP2001513511 A5 JP 2001513511A5 JP 2000506991 A JP2000506991 A JP 2000506991A JP 2000506991 A JP2000506991 A JP 2000506991A JP 2001513511 A5 JP2001513511 A5 JP 2001513511A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- patient
- end product
- glycation end
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 description 17
- 239000007795 chemical reaction product Substances 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 230000036252 glycation Effects 0.000 description 8
- 201000001320 Atherosclerosis Diseases 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000001973 epigenetic effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 3
- 102100029599 Advanced glycosylation end product-specific receptor Human genes 0.000 description 2
- 101001061840 Homo sapiens Advanced glycosylation end product-specific receptor Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/905,709 US7101838B2 (en) | 1997-08-05 | 1997-08-05 | Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts |
| US08/905,709 | 1997-08-05 | ||
| PCT/US1998/016303 WO1999007402A1 (en) | 1997-08-05 | 1998-08-05 | METHOD TO PREVENT ACCELERATED ATHEROSCLEROSIS USING (sRAGE) SOLUBLE RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCTS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009236481A Division JP4976475B2 (ja) | 1997-08-05 | 2009-10-13 | 後生的グリケーション最終生成物の可溶性レセプター（ｓＲＡＧＥ）を用いて加速性アテローム性動脈硬化症を予防する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2001513511A JP2001513511A (ja) | 2001-09-04 |
| JP2001513511A5 true JP2001513511A5 (https=) | 2009-05-28 |
| JP4426090B2 JP4426090B2 (ja) | 2010-03-03 |
Family
ID=25421326
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000506991A Expired - Fee Related JP4426090B2 (ja) | 1997-08-05 | 1998-08-05 | 後生的グリケーション最終生成物の可溶性レセプター（ｓＲＡＧＥ）を用いて加速性アテローム性動脈硬化症を予防する方法 |
| JP2009236481A Expired - Fee Related JP4976475B2 (ja) | 1997-08-05 | 2009-10-13 | 後生的グリケーション最終生成物の可溶性レセプター（ｓＲＡＧＥ）を用いて加速性アテローム性動脈硬化症を予防する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009236481A Expired - Fee Related JP4976475B2 (ja) | 1997-08-05 | 2009-10-13 | 後生的グリケーション最終生成物の可溶性レセプター（ｓＲＡＧＥ）を用いて加速性アテローム性動脈硬化症を予防する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7101838B2 (https=) |
| EP (1) | EP1011706B1 (https=) |
| JP (2) | JP4426090B2 (https=) |
| AT (1) | ATE253929T1 (https=) |
| AU (1) | AU758252B2 (https=) |
| CA (1) | CA2299467A1 (https=) |
| DE (1) | DE69819751T8 (https=) |
| DK (1) | DK1011706T3 (https=) |
| ES (1) | ES2210800T3 (https=) |
| PT (1) | PT1011706E (https=) |
| WO (1) | WO1999007402A1 (https=) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6790443B2 (en) * | 1996-11-22 | 2004-09-14 | The Trustees Of Columbia University In The City Of New York | Method for treating symptoms of diabetes |
| US7258857B2 (en) * | 1996-11-22 | 2007-08-21 | The Trustees Of Columbia University In The City Of New York | Rage-related methods for treating inflammation |
| US7101838B2 (en) * | 1997-08-05 | 2006-09-05 | The Trustees Of Columbia University In The City Of New York | Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts |
| US6465422B1 (en) * | 1998-04-17 | 2002-10-15 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting tumor invasion or spreading in a subject |
| AU765719B2 (en) * | 1998-10-06 | 2003-09-25 | Trustees Of Columbia University In The City Of New York, The | Extracellular novel rage binding protein (EN-RAGE) and uses thereof |
| EP1307219A4 (en) * | 1999-08-13 | 2005-04-06 | Univ Columbia | METHODS OF INHIBITING BETA FIBRILLE BINDING BETA TO RAGE RECEPTOR, AND CONSEQUENCES THEREOF |
| US6613801B2 (en) | 2000-05-30 | 2003-09-02 | Transtech Pharma, Inc. | Method for the synthesis of compounds of formula I and their uses thereof |
| US6908741B1 (en) | 2000-05-30 | 2005-06-21 | Transtech Pharma, Inc. | Methods to identify compounds that modulate RAGE |
| US7087632B2 (en) | 2001-03-05 | 2006-08-08 | Transtech Pharma, Inc. | Benzimidazole derivatives as therapeutic agents |
| US7919670B1 (en) | 2000-08-14 | 2011-04-05 | The Trustees Of Columbia University In The City Of New York | Transgenic mice over-expressing receptor for advanced glycation endproduct (RAGE) in brain and uses thereof |
| AU2002213192A1 (en) * | 2000-10-13 | 2002-04-22 | The Trustees Of Columbia University In The City Of New York | A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury |
| CN1494425B (zh) | 2001-03-05 | 2011-12-07 | 特兰斯泰克制药公司 | 用作治疗剂的羧酰胺衍生物 |
| JP3837494B2 (ja) | 2001-03-19 | 2006-10-25 | 国立大学法人金沢大学 | 可溶型ｒａｇｅタンパク質 |
| JP4481011B2 (ja) | 2002-03-05 | 2010-06-16 | トランス テック ファーマ，インコーポレイテッド | リガンドのｒａｇｅとの相互作用を阻害する単環式および二環式アゾール誘導体 |
| MXPA05001758A (es) * | 2002-08-16 | 2005-08-19 | Wyeth Corp | Composiciones y metodos para el tratamiento de trastornos asociados a receptor para productos finales de glicatacion avanzada (rage). |
| US8067371B2 (en) * | 2003-05-09 | 2011-11-29 | The Trustees Of Columbia University In The City Of New York | RAGE G82S-related methods and compositions for treating inflammatory disorders |
| EP1635823A1 (en) * | 2003-05-20 | 2006-03-22 | TransTech Pharma Inc. | Rage antagonists as agents to reverse amyloidosis and diseases associated therewith |
| WO2006012415A2 (en) * | 2004-07-20 | 2006-02-02 | Critical Therapeutics, Inc. | Rage protein derivatives |
| KR20070057818A (ko) * | 2004-08-03 | 2007-06-07 | 트랜스테크 파르마, 인크. | Ｒａｇｅ 융합 단백질 및 이의 사용 방법 |
| JP5188804B2 (ja) * | 2004-08-03 | 2013-04-24 | トランステック ファーマ，インコーポレイティド | Ｒａｇｅ融合タンパク質及びその使用方法 |
| US20060084145A1 (en) | 2004-09-27 | 2006-04-20 | Anderson Glenn M | sRAGE mimetibody, compositions, methods and uses |
| MX2007011411A (es) * | 2005-03-17 | 2007-11-13 | Univ Columbia | Interaccion rage/diaphanous y composiciones relacionadas y metodos. |
| AU2006327353B2 (en) * | 2005-12-23 | 2011-11-24 | Gcoder Systems Ab | Positioning pattern |
| KR20080105066A (ko) * | 2006-02-09 | 2008-12-03 | 트랜스테크 파르마, 인크. | Ｒａｇｅ 융합 단백질 및 이의 사용 방법 |
| AU2007248784B2 (en) | 2006-05-05 | 2013-11-21 | Vtv Therapeutics Llc | RAGE fusion proteins, formulations, and methods of use thereof |
| WO2008100470A2 (en) * | 2007-02-15 | 2008-08-21 | Transtech Pharma, Inc. | Rage - immunoglobulin fusion proteins |
| US20100254983A1 (en) * | 2007-06-07 | 2010-10-07 | Ann Marie Schmidt | Uses of rage antagonists for treating obesity and related diseases |
| EP2158210B1 (en) | 2007-06-14 | 2015-12-09 | Galactica Pharmaceuticals, Inc. | Rage fusion proteins |
| CL2008002053A1 (es) | 2007-07-17 | 2009-05-22 | Hoffmann La Roche | Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion. |
| CL2008002054A1 (es) | 2007-07-17 | 2009-05-29 | Hoffmann La Roche | Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico. |
| MX2010012473A (es) | 2008-05-23 | 2011-02-23 | Siwa Corp | Metodos, composiciones y aparato para facilitar la regeneracion. |
| US9034341B2 (en) | 2009-04-20 | 2015-05-19 | Transtech Pharma, Llc | Control of RAGE fusion protein glycosylation and RAGE fusion protein compositions |
| ES2467923T3 (es) | 2009-09-30 | 2014-06-13 | Transtech Pharma, Llc | Derivados de imidazol substituidos para el tratamiento de la enfermedad de Alzheimer |
| ES2550667T3 (es) | 2010-02-18 | 2015-11-11 | Vtv Therapeutics Llc | Derivados de fenilheteroarilo y métodos de uso de los mismos |
| US9649376B2 (en) | 2010-09-27 | 2017-05-16 | Siwa Corporation | Selective removal of age-modified cells for treatment of atherosclerosis |
| US8721571B2 (en) | 2010-11-22 | 2014-05-13 | Siwa Corporation | Selective removal of cells having accumulated agents |
| WO2012135616A1 (en) * | 2011-03-31 | 2012-10-04 | Siwa Corporation | Vaccination against advanced glycation end-products |
| WO2013103688A1 (en) * | 2012-01-03 | 2013-07-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human soluble receptors for advanced glycation end products (srage), methods of preparing human srage, and treatment methods using srage |
| US9717710B2 (en) | 2012-10-05 | 2017-08-01 | Vtv Therapeutics Llc | Treatment of mild and moderate Alzheimer's disease |
| CA2903946A1 (en) * | 2013-03-08 | 2014-09-12 | Zora Biosciences Oy | Non-high density lipoprotein derived cvd markers |
| CN107001459B (zh) | 2014-09-19 | 2021-11-23 | Siwa有限公司 | 用于治疗炎症和自身免疫紊乱的抗age抗体 |
| US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
| US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
| PT3337829T (pt) | 2016-02-19 | 2020-02-10 | Siwa Corp | Método e composição para o tratamento do cancro, matando células cancerosas metastáticas e prevenindo as metástases do cancro usando anticorpos para produtos finais de glicação avançada (pga) |
| CA3057829A1 (en) | 2016-04-15 | 2017-10-19 | Siwa Corporation | Anti-age antibodies for treating neurodegenerative disorders |
| WO2017222535A1 (en) | 2016-06-23 | 2017-12-28 | Siwa Corporation | Vaccines for use in treating various diseases and disorders |
| US10925937B1 (en) | 2017-01-06 | 2021-02-23 | Siwa Corporation | Vaccines for use in treating juvenile disorders associated with inflammation |
| US10858449B1 (en) | 2017-01-06 | 2020-12-08 | Siwa Corporation | Methods and compositions for treating osteoarthritis |
| US10995151B1 (en) | 2017-01-06 | 2021-05-04 | Siwa Corporation | Methods and compositions for treating disease-related cachexia |
| US10961321B1 (en) | 2017-01-06 | 2021-03-30 | Siwa Corporation | Methods and compositions for treating pain associated with inflammation |
| CA3059803A1 (en) | 2017-04-13 | 2018-10-18 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
| US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
| WO2019190822A1 (en) | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
| WO2019190823A1 (en) | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
| JP7464591B2 (ja) | 2018-10-10 | 2024-04-09 | ブイティーブイ・セラピューティクス・エルエルシー | ［３－（４－｛２－ブチル－１－［４－（４－クロロ－フェノキシ）－フェニル］－１ｈ－イミダゾール－４－イル｝－フェノキシ）－プロピル］－ジエチル－アミンの代謝産物 |
| WO2022089639A1 (zh) * | 2020-10-30 | 2022-05-05 | 深圳普罗吉医药科技有限公司 | 人血清白蛋白在治疗疾病中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585344A (en) | 1984-03-19 | 1996-12-17 | The Rockefeller University | Liver-derived receptors for advanced glycosylation endproducts and uses thereof |
| US5605885A (en) * | 1988-05-05 | 1997-02-25 | Entremed, Inc. | Method for stimulating the immune system |
| WO1992010579A1 (fr) | 1990-12-07 | 1992-06-25 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | PROCEDE DE PRODUCTION DE D-α-AMINOACIDES |
| CN1134803A (zh) | 1996-01-24 | 1996-11-06 | 沈阳市大东副食品商场 | 乘车游乐自选购物系统 |
| AU1832797A (en) | 1996-01-26 | 1997-08-20 | Trustees Of Columbia University In The City Of New York, The | A polypeptide from lung extract which binds amyloid-beta peptide |
| US5864018A (en) | 1996-04-16 | 1999-01-26 | Schering Aktiengesellschaft | Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor |
| AU2696097A (en) | 1996-04-16 | 1997-11-07 | Schering Aktiengesellschaft | Advanced glycosylation end-product receptor peptides and uses therefor |
| US5688653A (en) | 1996-06-27 | 1997-11-18 | The Picower Institute For Medical Research | 3-alkylamino-2-hydroxy-4-hydroxymethyl-2-cyclopenten-1-one advanced glycosylation endproducts and methods of use therefor |
| US6790443B2 (en) | 1996-11-22 | 2004-09-14 | The Trustees Of Columbia University In The City Of New York | Method for treating symptoms of diabetes |
| US6555651B2 (en) | 1997-10-09 | 2003-04-29 | The Trustees Of Columbia University In The City Of New York | Ligand binding site of rage and uses thereof |
| US7101838B2 (en) | 1997-08-05 | 2006-09-05 | The Trustees Of Columbia University In The City Of New York | Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts |
| EP1307219A4 (en) | 1999-08-13 | 2005-04-06 | Univ Columbia | METHODS OF INHIBITING BETA FIBRILLE BINDING BETA TO RAGE RECEPTOR, AND CONSEQUENCES THEREOF |
-
1997
- 1997-08-05 US US08/905,709 patent/US7101838B2/en not_active Expired - Fee Related
-
1998
- 1998-08-05 AU AU88239/98A patent/AU758252B2/en not_active Ceased
- 1998-08-05 WO PCT/US1998/016303 patent/WO1999007402A1/en not_active Ceased
- 1998-08-05 JP JP2000506991A patent/JP4426090B2/ja not_active Expired - Fee Related
- 1998-08-05 AT AT98939876T patent/ATE253929T1/de active
- 1998-08-05 DE DE69819751T patent/DE69819751T8/de active Active
- 1998-08-05 PT PT98939876T patent/PT1011706E/pt unknown
- 1998-08-05 ES ES98939876T patent/ES2210800T3/es not_active Expired - Lifetime
- 1998-08-05 EP EP98939876A patent/EP1011706B1/en not_active Expired - Lifetime
- 1998-08-05 CA CA002299467A patent/CA2299467A1/en not_active Abandoned
- 1998-08-05 DK DK98939876T patent/DK1011706T3/da active
-
2005
- 2005-12-27 US US11/319,949 patent/US7494972B2/en not_active Expired - Fee Related
-
2009
- 2009-10-13 JP JP2009236481A patent/JP4976475B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001513511A5 (https=) | ||
| Spencer et al. | Cetirizine: a reappraisal of its pharmacological properties and therapeutic use in selected allergic disorders | |
| Iannini | The safety profile of moxifloxacin and other fluoroquinolones in special patient populations | |
| EP0278821B1 (fr) | Utilisation d'antagonistes de la morphine dans la préparation de médicaments à effet immunomodulateur et anti-viral, destinés notamment à traiter les états immuno-déficitaires acquis | |
| RU2301063C2 (ru) | Форма для трансэпикутального введения для лечения синдрома усталых ног | |
| US20140051722A1 (en) | Topical lfa-1 antagonists for use in localized treatment of immune related disorders | |
| ES2173641T3 (es) | Composicion de derivados opiaceos para la fabricacion de medicamentos. | |
| AU2004233846A1 (en) | Compositions for affecting weight loss | |
| JPH06183967A (ja) | 免疫炎症性疾患の治療方法 | |
| CA1238275A (en) | Menthol enhancement of transdermal drug delivery | |
| AU740504B2 (en) | Use of descarboethoxyloratadine for the manufacture of a medicament for the treatment of urinary incontinence, motion sickness and vertigo | |
| JP2001520989A (ja) | 哺乳動物における欲求を減少する方法 | |
| JP2009535410A (ja) | ピロロキノリンキノンおよびその使用 | |
| BRPI0610851A2 (pt) | associação entre a ferroquina e um derivado de artemisinina, composição farmacêutica, utilização da referida associação e kit | |
| TW200526216A (en) | Use of a pyrazole derivative for preparing medicinal products that are useful in the prevention and treatment of dyslipidaemias and of diseases related to dyslipidaemias and-or to obesity | |
| US20070259014A1 (en) | Compositions for and Methods for Treating Hiv | |
| ES2343166T3 (es) | Activadores para el receptor activado por proliferador de peroxisoma. | |
| Fenton et al. | Telmisartan/hydrochlorothiazide: in the treatment of essential hypertension | |
| JP2003535965A5 (https=) | ||
| US6235793B1 (en) | Use of agonists of adrenergic β-3 receptors for preparing wound-healing medicines | |
| JP2002514404A5 (https=) | ||
| CA2474703A1 (en) | Therapeutic agent of glaucoma comprising bunazosin and prostaglandins | |
| US20050234024A1 (en) | Materials and methods for the treatment of ulcerative colitis | |
| Howarth | A review of the tolerability and safety of levocabastine eye drops and nasal spray. Implications for patient management | |
| MA28036A1 (fr) | Utilisation d'oxcarbazepine dans le traitement de la douleur liee a la neuropathie diabetique et dans l'amelioration du sommeil |